Adempas

Land: New Zealand

Sprog: engelsk

Kilde: Medsafe (Medicines Safety Authority)

Aktiv bestanddel:

Riociguat 1mg

Tilgængelig fra:

Bayer New Zealand Limited

INN (International Name):

Riociguat 1 mg

Dosering:

1 mg

Lægemiddelform:

Film coated tablet

Sammensætning:

Active: Riociguat 1mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Recept type:

Prescription

Fremstillet af:

Bayer AG

Terapeutiske indikationer:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Produkt oversigt:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Autorisation dato:

2014-06-25